DEFA14A: Vaxart Urges Stockholders to Approve Reverse Stock Split to Maintain Nasdaq Listing

Vaxart's Founder and CSO, Dr. Sean Tucker, released a video urging stockholders to vote for a reverse stock split to regain compliance with Nasdaq's minimum bid price rule.

Summary

• Vaxart, Inc. (Nasdaq: VXRT) has announced a video update from Dr. Sean Tucker, its Founder and Chief Scientific Officer, encouraging stockholders to vote FOR Proposal No. 2.
• Proposal No. 2 seeks to grant the Board of Directors the authority to implement a reverse stock split.
• The primary objective of this reverse stock split is to enable Vaxart to regain compliance with Nasdaq's minimum bid price rule, which is essential for continued listing.
• The company is actively addressing common misconceptions about the reverse stock split proposal through an attached fact sheet to ensure stockholders have accurate information.
• Stockholders of record as of March 26, 2025, are urged to cast their votes by 11:59 p.m. Eastern Time on June 1, 2025.
• Vaxart also reminds stockholders who previously voted against Proposal No. 2 that they have the option to change their vote in favor of the proposal.
• Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary pill-based delivery platform.
• Their vaccine candidates are designed for easy administration, storage, and shipping without refrigeration, and they eliminate the risk of needle-stick injuries.
• Current development programs include oral pill vaccines targeting coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV).

Sentiment

Score: 4

Explanation: While the company is taking a necessary proactive step to address Nasdaq compliance, the underlying reason for the reverse split (low stock price) is a negative indicator. The active communication from management is a positive, but the overall situation presents challenges.

Positives

• The company is taking proactive measures to address its Nasdaq listing compliance, which is critical for maintaining market access and liquidity.
• Management, specifically Dr. Sean Tucker, is actively communicating with stockholders through a video update to clarify the importance of the proposal and address potential misconceptions.
• Vaxart continues to advance its pipeline of oral recombinant vaccines, including candidates for major infectious diseases and an immune-oncology indication.

Negatives

• The necessity of a reverse stock split indicates that Vaxart's stock price has fallen below Nasdaq's minimum bid price requirement, signaling underlying market concerns or performance challenges.
• Reverse stock splits can sometimes be perceived negatively by investors, potentially leading to short-term stock price volatility or a decrease in investor confidence if the underlying issues are not resolved.

Risks

• Forward-looking statements contained in the filing are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the company's control, meaning actual results could differ materially.
• Material factors affecting business operations and financial performance include those detailed under Item 1A Risk Factors in Vaxart's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.
• There is no guarantee that the proposed reverse stock split, even if approved and implemented, will successfully enable Vaxart to regain or maintain compliance with the Nasdaq minimum bid price requirement.

Future Outlook

Vaxart's immediate future outlook is focused on successfully implementing the reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. Concurrently, the company plans to continue the development of its pipeline of oral recombinant vaccines for various indications.

Management Comments

• "Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025."
• "Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal."
• "Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 1, 2025."
• "The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal."

Industry Context

Clinical-stage biotechnology companies like Vaxart often face challenges in maintaining stock prices above exchange minimums due to the inherent risks, long development timelines, and significant capital requirements of drug development. Reverse stock splits are a common strategic tool employed by such companies to avoid delisting, enhance stock liquidity, and potentially attract a broader investor base by increasing the per-share price.

Corporate Governance

Stakeholder Impact

• Shareholders will be directly impacted by the reverse stock split, which will reduce the number of outstanding shares and proportionally increase the per-share price. This action is intended to preserve the company's Nasdaq listing, thereby maintaining liquidity and the viability of their investment.
• Employees may benefit from the company maintaining its public listing, which can contribute to overall corporate stability and potentially morale.
• Customers and partners are not directly impacted by this corporate action, but maintaining a public listing can enhance the company's credibility and operational continuity.

Next Steps

• Stockholders are required to vote on Proposal No. 2 (reverse stock split) by the deadline of June 1, 2025, 11:59 p.m. Eastern Time.
• If approved by stockholders, the Board of Directors will then decide on the timing and specific terms of the reverse stock split implementation.
• Vaxart will continue its ongoing development programs for its oral recombinant vaccine candidates.

Key Dates

Recommendation

Keywords

Vaxart, VXRT, reverse stock split, Nasdaq compliance, minimum bid price, oral vaccines, biotechnology, clinical-stage, coronavirus vaccine, norovirus vaccine, influenza vaccine, HPV vaccine, proxy statement, stockholder vote